Arvinas' high P/S ratio could be worrisome as revenue forecasts are not promising. The anticipated future revenues may not sustain the current positive sentiment. Without significant improvements, these prices may not be deemed reasonable.
Sean Cassidy expressed confidence in the company's future and the promising clinical development and commercial opportunity for the PROTAC(R) protein degrader pipeline. The company's leadership acknowledged Cassidy's pivotal role in creating Arvinas' strong financial profile.
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Arvinas Stock Forum
First Pivotal Data for Revolutionary Breast Cancer Drug to be Unveiled at ASCO 2025 Late-Breaking Session
Breakthrough Cancer Treatment ARV-393 Demonstrates Powerful Results Against Lymphoma in Latest Research
First-Ever PROTAC Cancer Drug Hits Major Trial Milestone: What This Means
• $ABM Industries (ABM.US)$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp (AMT.US)$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight (CHD.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy (CHWY.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene (CNC.US)$ : Credit Suisse Upgrades to Outperform from...
• $Cigna Group (CI.US)$ : Cowen Upgrades to Outperform from Market Perform - PT $329 (from $242)
• $DLocal (DLO.US)$ : New Street Research Upgrades to Buy from Neutral - PT $38
• $Goodyear Tire & Rubber (GT.US)$ : CFRA Upgrades to Buy from Hold - PT $20 (from $24)
• $Match group (MTCH.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $115 (from $140)
• $Prestige Consumer Healthcare (PBH.US)$ : Oppenheimer Upgrades to Outperform from Perform - P...
• $Acutus Medical (AFIB.US)$ : BTIG Upgrades to Buy from Neutral - PT $2
• $Antero Midstream (AM.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $13 (from $12)
• $Autohome (ATHM.US)$ : Citigroup Upgrades to Buy from Neutral - PT $30
• $Fifth Third Bancorp (FITB.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $52
• $Kinder Morgan (KMI.US)$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $21
• $MSCI Inc (MSCI.US)$...
No comment yet